UPDATE : Thursday, November 14, 2019
‘MDM2 gene’ may be associated with hyperprogression after immunotherapy
Oncology researchers around the world are paying keen attention to MDM2 (mo...
by Kim Yun-mi  |  2019-05-29 12:35
Invossa poses almost no safety threat: regulator
The Ministry of Food and Drug Safety said there was no significant concern ...
by Lee Hye-seon  |  2019-05-28 16:02
Brazil OKs Samsung Bioepis’ trastuzumab biosimilar
Brazil’s Agencia Nacional de Vigilancia Sanitaria has granted marketing aut...
by Lee Han-soo  |  2019-05-27 15:52
‘Shareholders can surely win lawsuit against Kolon’
Law firm Hankyul is pursuing a lawsuit against Kolon Life Science and Kolon...
by Jeong Sae-im  |  2019-05-24 19:34
‘Kolon’s extra data insufficient to explain Invossa mislabeling’
The Ministry of Food and Drug Safety said additional material submitted by ...
by Lee Hye-seon  |  2019-05-23 14:51
Prosecutors seek arrest warrant of Samsung BioLogics CEO
The Seoul Central District Prosecutors Office is seeking an arrest warrant ...
by Lee Han-soo  |  2019-05-23 11:19
[News Focus] Kolon, regulator rapped for not doing enough to quell concerns of patients
More than 50 days have passed since the Ministry of Food and Drug Safety (M...
by Jeong Sae-im  |  2019-05-22 11:59
Legislator, activists call for revoking Invossa license, conducting probes
A lawmaker and civic groups urged the government to nullify the license of ...
by Jeong Sae-im  |  2019-05-21 16:03
Kolon to follow 3,700 Invossa-treated patients for 15 years
Kolon Life Science said it would conduct a long-term follow-up study on ove...
by Jeong Sae-im  |  2019-05-17 15:38
Will Celltrion CEO’s bet on ‘bio valley’ pay off?
“It’s been 19 years since I started this business. The first decade was a t...
by Jeong Sae-im  |  2019-05-17 13:21
CHA Biotech’s operating income plunges 92% in Q1
CHA Biotech said in a public filing on Wednesday that it recorded 124.4 bil...
by Jeong Sae-im  |  2019-05-16 13:41
KangStem Biotech completes stem cell drug plant
“KangStem Biotech aims to become a leader in the global stem cell therapy m...
by Jeong Sae-im  |  2019-05-16 11:27
Samsung BioLogics in tight spot amid probe, shareholders’ lawsuit
Prosecutors are speeding up the probe into Samsung BioLogics for alleged ac...
by Jeong Sae-im  |  2019-05-14 14:10
Celltrion’s operating income down 33% in Q1
Biopharmaceutical firm Celltrion said it suffered a 32.9 percent decline in...
by Jeong Sae-im  |  2019-05-09 15:26
If Invossa license gets revoked, Kolon should return $13 million to Mundipharma
The licensing deal between Kolon Life Science and Mundipharma for osteoarth...
by Jeong Sae-im  |  2019-05-08 15:33
Inspection will clear all suspicions over Invossa: TissueGene
Kolon TissueGene finally broke silence amid a growing suspicion that it mig...
by Jeong Sae-im  |  2019-05-08 14:32
Kolon might have covered up Invossa mislabeling for 2 years
Kolon TissueGene said in a public filing that it notified its parent compan...
by Jeong Sae-im  |  2019-05-07 15:55
When will regulator visit Kolon TissueGene for inspection?
The Ministry of Food and Drug Safety is likely to decide in mid-May on when...
by Lee Hye-seon  |  2019-05-02 14:09
Civic group files complaint against Kolon, regulator
A non-government consumer group has complained with the prosecution against...
by Jeong Sae-im  |  2019-04-30 14:59
FDA OKs Celltrion’s antibiotics generic
Celltrion said that the U.S. Food and Drug Administration has approved Line...
by Lee Han-soo  |  2019-04-30 11:22
Back to Top